Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 3Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Endocrine 2

Conditions

Breast Neoplasms 1476Neoplasms 999Colorectal Neoplasms 830Carcinoma, Non-Small-Cell Lung 724Carcinoma, Hepatocellular 683Stomach Neoplasms 647Lung Neoplasms 584Prostatic Neoplasms 543Pancreatic Neoplasms 456Rectal Neoplasms 338Uterine Cervical Neoplasms 303Colonic Neoplasms 295Neoplasm Metastasis 292Ovarian Neoplasms 285Esophageal Neoplasms 279Recurrence 278Leukemia, Myeloid, Acute 253Head and Neck Neoplasms 241Multiple Myeloma 232Brain Neoplasms 204Polycystic Ovary Syndrome 200Nasopharyngeal Carcinoma 198Melanoma 198Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Urinary Bladder Neoplasms 193Lymphoma 178Liver Neoplasms 178Endometrial Neoplasms 159Motor Activity 147Lymphoma, Large B-Cell, Diffuse 141

Interventions

candesartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × Essential Hypertension × Clear all
NCT06090617 2024-03-19

WHYSKI

University Hospital Padova

Unknown
35 enrolled
Endocrine

Essential Hypertension, Hyperaldosteronism, Hypertension, Adrenocortical Adenoma

NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡